...
【24h】

Cladribine modifies functional properties of microglia

机译:Cladribine改变了微胶质细胞的功能性质

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cladribine (CdA), an oral prodrug approved for the treatment of relapsing multiple sclerosis, selectively depletes lymphocytes. CdA passes the blood-brain barrier, suggesting a potential effect on central nervous system (CNS) resident cells. We examined if CdA modifies the phenotype and function of naive and activated primary mouse microglia, when applied in the concentrations 0 center dot 1-1 mu M that putatively overlap human cerebrospinal fluid (CSF) concentrations. Primary microglia cultures without stimulation or in the presence of proinflammatory lipopolysaccharide (LPS) or anti-inflammatory interleukin (IL)-4 were treated with different concentrations of CdA for 24 h. Viability was assessed by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Phagocytotic ability and morphology were examined by flow cytometry and random migration using IncuCyte Zoom and TrackMate. Change in gene expression was examined by quantitative polymerase chain reaction (qPCR) and protein secretion by Meso Scale Discovery. We found that LPS and IL-4 up-regulated deoxycytidine kinase (DCK) expression. Only activated microglia were affected by CdA, and this was unrelated to viability. CdA 0 center dot 1-1 mu M significantly reduced granularity, phagocytotic ability and random migration of activated microglia. CdA 10 mu M increased the IL-4-induced gene expression of arginase 1 (Arg1) and LPS-induced expression of IL-1 beta, tumor necrosis factor (TNF), inducible nitric oxide synthase (iNOS) and Arg1, but protein secretion remained unaffected. CdA 10 mu M potentiated the increased expression of anti-inflammatory TNF receptor 2 (TNF-R2) but not TNF-R1 induced by LPS. This suggests that microglia acquire a less activated phenotype when treated with 0 center dot 1-1 mu M CdA that putatively overlaps human CSF concentrations. This may be related to the up-regulated gene expression of DCK upon activation, and suggests a potential alternative mechanism of CdA with direct effect on CNS resident cells.
机译:Cladribine(CDA),批准用于复发多发性硬化症的口腔前药,选择性地耗尽淋巴细胞。 CDA通过血脑屏障,表明对中枢神经系统(CNS)驻留电池的潜在影响。我们检查了CDA是否改变了幼稚和活化的原鼠髓小鼠小鼠的表型和功能,当施加在浓度0中心点1-1μm时,借助于人脑脊髓液(CSF)浓度。在不刺激或存在促炎脂多糖(LPS)或抗炎白细胞介素(IL)-4的情况下用不同浓度的CDA处理24小时的初级微胶质细胞培养物。通过MTT [3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑粒溴化物测定评估活力。通过流式细胞术检测吞噬细胞能力和形态,并使用Clucyte Zoom和Trackmate进行随机迁移。通过定量聚合酶链反应(QPCR)和Meso Scale Discovery的蛋白质分泌检查基因表达的变化。我们发现LPS和IL-4上调的脱氧胞苷激酶(DCK)表达。只有活化的微胶质细胞受CDA的影响,并且这与可生存不相关。 CDA 0中心点1-1μm显着降低粒度,吞噬能力和活性微胶囊的随机迁移。 CDA 10 mu m增加了氨基酶1(ARG1)和LPS诱导的IL-1β,肿瘤坏死因子(TNF),诱导型一氧化氮合酶(InOS)和Arg1的IL-4诱导的基因表达,但蛋白质分泌仍未受到影响。 CDA10μm调节抗炎TNF受体2(TNF-R2)的表达增加而不是LPS诱导的TNF-R1。这表明在用0中心点1-1μMCDA处理时,微胶质细胞捕获较少的活化表型,其借助于人的CSF浓度。这可能与激活后DCK的上调基因表达有关,并表明CDA具有直接影响CNS驻留电池的潜在替代机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号